MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
RadNet Net Income 2011-2026 | RDNT
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income RadNet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.7 M | 2.79 M | 3.04 M | 10.6 M | 24.7 M | -14.8 M | 14.8 M | 32.2 M | 53 K | 7.23 M | 7.71 M | 1.38 M | 2.12 M | 64.5 M | 7.23 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64.5 M | -18.7 M | 9.66 M |
Quarterly Net Income RadNet
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.42 M | 14.5 M | - | 3.21 M | -2.98 M | - | 17.5 M | 8.37 M | -21 M | - | 668 K | 7.9 M | 3.01 M | - | 16.2 M | 2.87 M | 9.46 M | - | 6.16 M | -10.6 M | -16.4 M | 10.4 M | 3.2 M | 4.9 M | -3.73 M | 29.1 M | 5.04 M | 5.41 M | -7.34 M | -7.28 M | 3.23 M | 5.31 M | -1.21 M | 3.68 M | 1.65 M | 3.62 M | -1.72 M | 881 K | 7.99 M | 3.4 M | -4.55 M | 4.2 M | 4.45 M | 5.14 M | -12.4 M | 1.24 M | -467 K | 2.69 M | -1.34 M | 56.6 M | 5.05 M | 2.95 M | -111 K | 4.55 M | 39 K | 3.52 M | -876 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 56.6 M | -21 M | 3.49 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.21 B | $ 113.86 | -0.85 % | $ 34.6 B |  USA |
 |
Danaher Corporation
DHR
|
3.61 B | $ 190.59 | -0.8 % | $ 136 B | USA |
 |
DexCom
DXCM
|
836 M | $ 63.64 | 0.68 % | $ 24.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 16.32 | -0.61 % | $ 493 M | USA |
 |
Guardant Health
GH
|
-416 M | $ 90.59 | 1.04 % | $ 11.4 B | USA |
 |
ICON Public Limited Company
ICLR
|
791 M | $ 107.81 | -1.66 % | $ 8.89 B |  Irlanda |
 |
Illumina
ILMN
|
-1.22 B | $ 127.23 | -0.4 % | $ 20.2 B | USA |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 17.63 | -1.07 % | $ 939 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Laboratory Corporation of America Holdings
LH
|
876 M | $ 274.85 | 0.14 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
234 M | $ 75.68 | -0.28 % | $ 5.11 B | USA |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Medpace Holdings
MEDP
|
451 M | $ 493.63 | -0.48 % | $ 14.2 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.99 | 4.23 % | $ 176 M |  China |
 |
Myriad Genetics
MYGN
|
-366 M | $ 4.62 | -1.07 % | $ 428 M | USA |
 |
Co-Diagnostics
CODX
|
-46.9 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
NeoGenomics
NEO
|
-108 M | $ 7.98 | -0.5 % | $ 1.02 B | USA |
 |
Aspira Women's Health
AWH
|
-12.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Neogen Corporation
NEOG
|
-1.09 B | $ 9.93 | 3.82 % | $ 2.15 B | USA |
 |
Natera
NTRA
|
-548 M | $ 207.69 | 1.38 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 17.24 | -0.52 % | $ 386 M | USA |
 |
Pacific Biosciences of California
PACB
|
-546 M | $ 1.4 | -1.76 % | $ 420 M | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
Precipio
PRPO
|
-363 K | $ 26.0 | 0.08 % | $ 41.7 M | USA |
 |
Personalis
PSNL
|
-81.3 M | $ 6.21 | -5.57 % | $ 368 M | USA |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 167.8 | -0.25 % | $ 8.32 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
Sotera Health Company
SHC
|
77.9 M | $ 14.86 | -0.1 % | $ 4.22 B | USA |
 |
Castle Biosciences
CSTL
|
18.2 M | $ 24.96 | 0.93 % | $ 693 M | USA |
 |
Soleno Therapeutics
SLNO
|
20.9 M | $ 52.25 | - | $ 2.66 B | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
-39 M | $ 1.6 | -9.09 % | $ 106 M | USA |
|
Biodesix
BDSX
|
-42.9 M | $ 14.71 | -4.21 % | $ 1.91 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
3.32 B | $ 26.99 | -0.79 % | $ 20 B |  Niderland |
 |
Thermo Fisher Scientific
TMO
|
6.7 B | $ 483.56 | -0.95 % | $ 182 B | USA |
 |
Trinity Biotech plc
TRIB
|
929 K | $ 0.61 | -1.34 % | $ 61.9 M | Irlanda |
 |
VolitionRx Limited
VNRX
|
-23.4 M | $ 0.17 | -0.89 % | $ 21.4 M |  Singapore |
 |
Waters Corporation
WAT
|
643 M | $ 301.9 | -0.72 % | $ 18 B | USA |
 |
QIAGEN N.V.
QGEN
|
425 M | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
-10.9 M | $ 2.59 | - | $ 84.1 K | USA |
 |
Biomerica
BMRA
|
-4.97 M | $ 2.08 | -4.13 % | $ 4.78 M | USA |
 |
BioNano Genomics
BNGO
|
-26.4 M | $ 1.14 | -1.3 % | $ 6.21 M | USA |
 |
Interpace Biosciences
IDXG
|
24.6 M | $ 2.02 | 2.54 % | $ 8.94 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.1 M | - | - | $ 9.42 M |  Israel |
 |
Celcuity
CELC
|
-177 M | $ 113.87 | -0.31 % | $ 5.32 B | USA |